Pricing Log in Create free account
Friday 6 November 2026 Export RVP’s income statement to Excel — free account

Retractable Technologies, Inc.

RVP Healthcare Medical Instruments & Supplies

Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024.

Revenue
−31.1%
EPS
0.00%
Free cash flow
+56.7%
Total debt
−32.9%

Quarter to June 2026, against a year earlier

0.57 0.00 0.00%
Market cap
$16.9M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
0.57
Beneish M
−15.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 59.21%

Capital & Financial Ratios $m

Size
Market Cap 16.94
Revenue ttm 33.90
Net income ttm (3.37)
Free cash flow ttm (5.11)
Net debt Q (39.15)
Valuation
P/E 0.00
Forward P/E 11.10
Price / sales 0.50
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.23
Financial health
Current ratio Q 4.93 (at or above 1.5: strong)
Debt / equity Q 0.01 (at or below 0.5: strong)
Interest coverage Q (275.18)
Growth
Revenue growth Q −31.07% (below 0%: shrinking)
Operating income growth Q −0.29% (below 0%: shrinking)
EPS, this year —
EPS, next year A —
Revenue, next year A −49.68% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.7×, against a ten-year median of 0.4×; over the ten years it ranged from −0.7× in 2024 to 8.1× in 2020.
P/S against its own 10 years 3.41%
10-year low 10-year high
P/B against its own 10 years 1.25%
10-year low 10-year high
EV/FCF against its own 10 years 66.46%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 47 45 37 40
Receivables 12 9 8 9
Inventory 18 19 17 16
Other 1 1 1 1
78 73 63 66
2023 2024 2025 Q'26
Payables 5 4 5 7
ST’ Debt 0 0 0 0
Other — — — —
9 9 10 13

Compound Annual Growth %

10y 5y 3y
Sales 2.62% (14.11%) (26.10%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.22% 8.32% (11.29%)

EPS $

Mar Jun Sep Dec Year
’26 (0.14) 0.09 — — —
’25 (0.35) 0.00 0.01 (0.08) (0.43)
’24 0.01 (0.48) (0.07) 0.13 (0.40)
’23 0.03 (0.13) (0.14) 0.00 (0.24)
’22 0.22 (0.11) 0.16 (0.13) 0.15
’21 0.52 0.31 0.19 0.61 1.63
’20 0.00 0.11 0.25 0.35 0.80
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 7 7 — — —
’25 8 10 10 9 38
’24 8 6 10 9 33
’23 11 8 10 14 44
’22 45 14 23 13 95
’21 50 42 36 59 188
’20 11 12 27 32 82
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 (1) (4) (1) (1) (7)
’24 (2) (3) (6) (1) (12)
’23 (4) (3) 8 2 3
’22 21 (8) (8) 12 17
’21 17 15 (13) 15 33
’20 2 (2) 9 10 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 (2) (4) (1) (1) (8)
’24 (2) (3) (7) (1) (13)
’23 (4) (3) 8 2 2
’22 16 (14) (12) 9 0
’21 4 (11) (22) 3 (26)
’20 2 (2) 0 (1) (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 30 34 33 42 82 188 95 44 33 38 34 +2.8% — — — —
Gross margin, % 34.67 28.91 30.72 33.83 45.21 50.62 29.80 20.89 (3.11) 0.12 (1.45) (34.6) pt
EBT (4) (4) (1) 3 26 75 5 (9) (4) (12) (3) +14.3%
EBT margin, % (12.38) (11.37) (4.07) 7.55 31.85 39.79 5.44 (20.45) (10.65) (32.08) (9.92) (19.7) pt
Net income (4) (4) (1) 3 24 56 5 (7) (12) (13) (3) +14.6%
Per share, $
Per share, $ Revenue 1.02 1.08 1.02 1.28 2.47 5.56 2.88 1.46 1.10 1.28 1.13 +2.6%
Earnings (0.15) (0.14) (0.06) 0.07 0.80 1.65 0.15 (0.24) (0.40) (0.43) (0.12) +12.4%
Cash flow (0.03) (0.09) (0.04) 0.07 0.57 0.97 0.51 0.09 (0.39) (0.24) (0.17) +27.2%
Capex (0.07) 0.00 (0.01) (0.02) (0.63) (1.72) (0.51) (0.03) (0.05) (0.02) (0.01) (13.5%)
Free cash flow (0.09) (0.09) (0.05) 0.05 (0.06) (0.75) 0.00 0.06 (0.43) (0.25) (0.17) +11.8%
Book value 0.96 0.85 0.78 0.87 1.50 2.93 3.24 3.32 2.91 2.48 2.43 +11.2%
Shares, m 29 32 33 33 33 34 33 30 30 30 30 +0.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 18.75 14.95 4.20 11.47 0.00 0.00 0.00 0.00 4.9
P/S 0.95 0.63 0.59 1.17 4.35 1.25 0.60 0.74 0.63 0.60 0.50 1.2
P/B 1.04 0.82 0.79 1.76 7.18 2.37 0.53 0.33 0.24 0.31 0.23 1.5
EV/Sales 0.54 0.30 0.30 0.91 3.94 1.00 0.07 (0.31) (0.69) (0.34) (0.65) 0.6
EV/FCF (5.91) (3.43) (6.35) 24.28 (157.13) (7.37) (112.85) (7.01) 1.74 1.71 4.32 (27.2)
Cash, $m
Cash, $m Operating cash flow (1) (3) (1) 2 19 33 17 3 (12) (7) (5) +27.5%
Capex (2) 0 0 (1) (21) (58) (17) (1) (1) (1) 0 (13.4%)
Free cash flow (3) (3) (2) 2 (2) (26) 0 2 (13) (8) (5) +12.0%
Balance, $m
Balance, $m Working capital 20 19 17 20 42 69 77 68 64 53 53 +11.9%
Net debt (12) (11) (10) (11) (34) (46) (50) (46) (43) (36) (39) +12.7%
Shareholders’ equity 28 27 26 29 50 99 107 99 87 74 73 +11.4%
Returns, %
Returns, % ROA (10.85) (11.54) (5.45) 6.42 36.94 35.87 2.41 (3.86) (7.12) (8.44) (2.49) +2.4 pt
ROIC (13.84) (14.96) (5.18) 10.63 92.90 85.74 (0.94) (13.41) (30.09) (34.56) (42.05) (20.7) pt
ROE (15.35) (16.53) (7.98) 9.30 68.81 75.15 4.72 (7.05) (13.03) (15.89) (4.84) (0.5) pt
People
People Employees 135 150 125 140 182 235 198 151 227 201 — +4.5%
Revenue/emp, $m 0.22 0.23 0.27 0.30 0.45 0.80 0.48 0.29 0.15 0.19 — (1.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Retractable Technologies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEPH Nephros Inc. $33.6M 18.0× 20.2× +18.01% (above 0%: growing) +66.67% (above 0%: growing) −251.52% (below 0%: shrinking) 58.45% 8.91% Compare
MLSS Milestone Scientific, Inc. $27.1M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
RVP Retractable Technologies, Inc. $16.9M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%)
BNGO Bionano Genomics, Inc. $15.4M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $12.7M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%) Compare
FEMY Femasys Inc. $11.0M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%) Compare
CUPR Cuprina Holdings (Cayman) Limited $10.4M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $8.2M — — — — −132.79% (below 0%: shrinking) — — Compare
LUCY Innovative Eyewear, Inc. $7.2M — (loss-making) — +74.46% (above 0%: growing) n/m +9.61% (above 0%: growing) 24.00% (168.73%) Compare
Median of peers $11.8M — — +21.82% — −33.93% 54.94% (78.15%)

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.22m 1.22m 7.17
2024 1.19m 1.19m 6.52
2023 1.15m 1.15m 10.34
2022 1.08m 8.58m 15.27
2021 11.52m 4.02m 64.53

Ownership

Directors and executive officers, together 59.50%
As Individuals 55.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Retractable Technologies, Inc. (RVP) Latest News

20 Aug

Impact 3 ·

14 Aug

Impact 4 · · Business Wire
Impact 3 · earnings
Impact 3 · · Business Wire
Impact 3 · · Associated Press Finance
Impact 3 · · Associated Press Finance

15 May

Impact 4 ·
Impact 3 · · Business Wire
Impact 3 ·
Impact 3 · · Business Wire

9 Apr

Impact 3 · · Business Wire

1 Apr

Impact 4 · · Zacks

27 Mar

Impact 4 · · Business Wire

20 Nov

Impact 3 · · ZacksAssociated Press FinanceStockStoryGuruFocus.comZacksGuruFocus.comGuruFocus.comMotley Fool

14 Nov

Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Business Wire

30 Sep

Impact 4 · · Business Wire
Impact 3 · · Business Wire

21 Aug

Impact 4 ·

23 Jul

Impact 3 · · Business Wire

19 Jun

Impact 4 · · Zacks

11 Apr

Impact 3 · · medicaldevice-network.com

10 Apr

Impact 3 ·

28 Mar

Impact 4 · · Business Wire
Impact 3 ·

20 Sep

Impact 4 · · Business Wire

29 Mar

Impact 3 · · Business Wire

29 Jan

Impact 4 · · Insider Monkey

22 Jan

Impact 4 · · InvestorPlace
stockrow.com/RVP · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com